Search Results - "GULBIS, Alison M"

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation by Saberian, Chantal, Abdel-Wahab, Noha, Abudayyeh, Ala, Rafei, Hind, Joseph, Jacinth, Rondon, Gabriela, Whited, Laura, Gruschkus, Stephen, Fa'ak, Faisal, Daher, May, Knape, Cristina, Safa, Houssein, Shoukier, Mahran, Suarez-Almazor, Maria E, Marcotulli, Megan, Ludford, Kaysia, Gulbis, Alison M, Konopleva, Marina, Ohanian, Maro, Ravandi, Farhad, Garcia-Manero, Guillermo, Oran, Betul, Popat, Uday R, Mehta, Rotesh, Alousi, Amin M, Daver, Naval, Champlin, Richard, Diab, Adi, Al-Atrash, Gheath

“…BackgroundImmune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction…”
Get full text

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities by Neelapu, Sattva S., Tummala, Sudhakar, Kebriaei, Partow, Wierda, William, Gutierrez, Cristina, Locke, Frederick L., Komanduri, Krishna V., Lin, Yi, Jain, Nitin, Daver, Naval, Westin, Jason, Gulbis, Alison M., Loghin, Monica E., de Groot, John F., Adkins, Sherry, Davis, Suzanne E., Rezvani, Katayoun, Hwu, Patrick, Shpall, Elizabeth J.

“…Key Points Chimeric antigen receptor (CAR)-T-cell therapy is a promising approach for the treatment of refractory malignancies, but is associated with unique…”
Get full text

Decrease post-transplant relapse using donor-derived expanded NK-cells by Ciurea, Stefan O., Kongtim, Piyanuch, Soebbing, Doris, Trikha, Prashant, Behbehani, Gregory, Rondon, Gabriela, Olson, Amanda, Bashir, Qaiser, Gulbis, Alison M., Indreshpal, Kaur, Rezvani, Katayoun, Shpall, Elizabeth J., Bassett, Roland, Cao, Kai, Martin, Andrew St, Devine, Steven, Horowitz, Mary, Pasquini, Marcelo, Lee, Dean A., Champlin, Richard E.

“…In this phase I/II clinical trial, we investigated the safety and efficacy of high doses of mb-IL21 ex vivo expanded donor-derived NK cells to decrease relapse…”
Get full text

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' by Neelapu, Sattva S., Tummala, Sudhakar, Kebriaei, Partow, Wierda, William, Locke, Frederick L., Lin, Yi, Jain, Nitin, Daver, Naval, Gulbis, Alison M., Adkins, Sherry, Rezvani, Katayoun, Hwu, Patrick, Shpall, Elizabeth J.

Get full text

Incidence of bacterial blood stream infections in patients with acute GVHD by Wallis, Whitney, Gulbis, Alison M, Wang, Tao, Lee, Catherine J, Sharma, Akshay, Williams, Kirsten M, Nishihori, Taiga, Prestidge, Tim, Gowda, Lohith, Byrne, Michael, Krem, Maxwell M, MacMillan, Margaret L, Kitko, Carrie L, Pidala, Joseph, Spellman, Stephen R, Lee, Stephanie J, Alousi, Amin M

“…Bacterial bloodstream infections (BSI) can be a substantial contributor to complications of GVHD treatment. The aim of this study was to determine the risk for…”
Get full text

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer by Ragoonanan, Dristhi, Khazal, Sajad J., Abdel-Azim, Hisham, McCall, David, Cuglievan, Branko, Tambaro, Francesco Paolo, Ahmad, Ali Haider, Rowan, Courtney M., Gutierrez, Cristina, Schadler, Keri, Li, Shulin, Di Nardo, Matteo, Chi, Linda, Gulbis, Alison M., Shoberu, Basirat, Mireles, Maria E., McArthur, Jennifer, Kapoor, Neena, Miller, Jeffrey, Fitzgerald, Julie C., Tewari, Priti, Petropoulos, Demetrios, Gill, Jonathan B., Duncan, Christine N., Lehmann, Leslie E., Hingorani, Sangeeta, Angelo, Joseph R., Swinford, Rita D., Steiner, Marie E., Hernandez Tejada, Fiorela N., Martin, Paul L., Auletta, Jeffery, Choi, Sung Won, Bajwa, Rajinder, Dailey Garnes, Natalie, Kebriaei, Partow, Rezvani, Katayoun, Wierda, William G., Neelapu, Sattva S., Shpall, Elizabeth J., Corbacioglu, Selim, Mahadeo, Kris M.

“…Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid…”
Get full text

Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies by Khouri, Issa F, Fernandez Curbelo, Irina, Turturro, Francesco, Jabbour, Elias J, Milton, Denái R, Bassett, Jr, Roland L, Vence, Luis M, Allison, James P, Gulbis, Alison M, Sharma, Padmanee

“…Prevention or treatment of relapsed lymphoid malignancies after hematopoietic stem cell transplantation (HSCT) requires novel strategies. We hypothesized that…”
Get full text

Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration by Kawedia, Jitesh D, Ramchandran, Sumankalai, Liu, Xiaoqian, Gulbis, Alison M, Titus, Mark, Bashir, Qaiser, Qazilbash, Muzaffar H, Champlin, Richard E, Ciurea, Stefan O

“…To compare the chemical stability of Captisol-enabled (CE) melphalan ("CE-melphalan"; Evomela, Acrotech Biopharma LLC) and propylene glycol (PG)-based…”
Get full text

Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial by Khouri, Issa F., Alzahrani, Kamal, Kantarjian, Hagop, Milton, Denái R., Gulbis, Alison M., Sasaki, Koji, Jain, Nitin, Short, Nicholas J., Kadia, Tapan, Daher, May, Rafei, Hind, Im, Jin S., Marin, David, Olson, Amanda L., Popat, Uday, Qazilbash, Muzaffar, Ramdial, Jeremy, Rondon, Gabriela, Srour, Samer, Kebriaei, Partow, Shpall, Elizabeth, Champlin, Richard, Jabbour, Elias J.

“…Here we report on the first prospective study evaluating the safety and long‐term survival when an escalating dose of inotuzumab ozogamicin (INO) (0.6, 1.2, or…”
Get full text

Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant by Al-Juhaishi, Taha, Wang, Yingjun, Milton, Denái R., Xu-Monette, Zijun Y., Jabbour, Elias, Daher, May, Im, Jin S., Bashir, Qaiser, Iyer, Swaminathan P., Marin, David, Olson, Amanda L., Popat, Uday, Qazilbash, Muzaffar, Rondon, Gabriela, Gulbis, Alison M., Champlin, Richard E., Young, Ken H., Khouri, Issa F.

“…Dual expression of MYC and BCL2 proteins (double-expressor lymphoma [DEL]) as well as cell of origin (COO) are important prognostic factors in patients with…”
Get full text

Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant by Khouri, Issa F, Milton, Denái R, Gulbis, Alison M, Jabbour, Elias J, Nastoupil, Loretta, Ledesma, Celina, Anderlini, Paolo, Bashir, Qaiser, Daher, May, Im, Jin S, Iyer, Swaminathan P, Marin, David, Mehta, Rohtesh S, Olson, Amanda L, Popat, Uday R, Qazilbash, Muzaffar, Saini, Neeraj, Samaniego, Felipe, Rondon, Gabriela, Medeiros, L Jeffrey, Champlin, Richard E

“…To compare outcomes between patients with relapsed follicular lymphoma who received a nonmyeloablative allogeneic stem cell transplant (alloSCT) and those who…”
Get full text

Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors by Mukherjee, Akash, Milton, Denái R., Jabbour, Elias J., Gulbis, Alison M., Kadia, Tapan, Jain, Nitin, Ledesma, Celina, Burger, Jan, Ferrajoli, Alessandra, Wierda, William, Medeiros, L. Jeffrey, Kantarjian, Hagop, Champlin, Richard, Khouri, Issa F.

“…We aimed to study the risks of graft-versus-host disease (GVHD), non-relapse mortality (NRM) and survival outcomes of allogeneic stem cell transplantation…”
Get full text

Program development of a preceptor bootcamp for operational pharmacy preceptors by Smith, Devlin V, Gautreaux, Stefani, Gulbis, Alison M, Bruno, Jeffrey J, Garey, Kevin, Roux, Ryan K, Varkey, Divya

“…Abstract Purpose To describe the development, design, and implementation of a pilot preceptor development bootcamp and feedback related to its feasibility and…”
Get full text

Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience by El-Haddad, Danielle, El Chaer, Firas, Vanichanan, Jackapat, Shah, Dimpy P., Ariza-Heredia, Ella J., Mulanovich, Victor E., Gulbis, Alison M., Shpall, Elizabeth J., Chemaly, Roy F.

“…The emergence of resistance to available antiviral drugs may cause higher Cytomegalovirus (CMV)-associated morbidity and mortality in hematopoietic cell…”
Get full text

Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer by Ragoonanan, Dristhi, Khazal, Sajad J., Abdel-Azim, Hisham, McCall, David, Cuglievan, Branko, Tambaro, Francesco Paolo, Ahmad, Ali Haider, Rowan, Courtney M., Gutierrez, Cristina, Schadler, Keri, Li, Shulin, Di Nardo, Matteo, Chi, Linda, Gulbis, Alison M., Shoberu, Basirat, Mireles, Maria E., McArthur, Jennifer, Kapoor, Neena, Miller, Jeffrey, Fitzgerald, Julie C., Tewari, Priti, Petropoulos, Demetrios, Gill, Jonathan B., Duncan, Christine N., Lehmann, Leslie E., Hingorani, Sangeeta, Angelo, Joseph R., Swinford, Rita D., Steiner, Marie E., Tejada, Fiorela N. Hernandez, Martin, Paul L., Auletta, Jeffery, Choi, Sung Won, Bajwa, Rajinder, Garnes, Natalie Dailey, Kebriaei, Partow, Rezvani, Katayoun, Wierda, William G., Neelapu, Sattva S., Shpall, Elizabeth J., Corbacioglu, Selim, Mahadeo, Kris M.

“…A Correction to this paper has been published: https://doi.org/10.1038/s41571-021-00497-x…”
Get full text

Pharmacokinetics: Unique Challenges in Blood Monitoring for Oncology Nurses by Kawedia, Jitesh D, Kalariya, Nilesh, Gulbis, Alison M, Andersson, Borje S, Myers, Alan L

“…Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion of drugs. Many chemotherapeutic agents have a sensitive PK index,…”
Get full text

Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit by Ragon, Brittany Knick, Mehta, Rohtesh S., Gulbis, Alison M., Saliba, Rima M., Chen, Julianne, Rondon, Gabriela, Popat, Uday R., Nieto, Yago, Oran, Betul, Olson, Amanda L., Patel, Krina, Hosing, Chitra M., Qazilbash, Muzaffar H., Shah, Nina, Kebriaei, Partow, Shpall, Elizabeth J., Champlin, Richard E., Alousi, Amin M.

“…We report outcomes of 60 patients with steroid-refractory (SR)-aGVHD treated with pentostatin. Almost half (47%) of patients had grade 4 GVHD—22% had stage 3–4…”
Get full text

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma by Chahoud, Jad, Sui, Dawen, Erwin, William D., Gulbis, Alison M., Korbling, Martin, Zhang, Mingzhi, Ahmed, Sairah, Alatrash, Gheath, Anderlini, Paolo, Ciurea, Stefan O., Oran, Betul, Fayad, Luis E., Bassett, Roland L., Jabbour, Elias J., Medeiros, L. Jeffrey, Macapinlac, Homer A., Young, Ken H., Khouri, Issa F.

“…Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or…”
Get full text

Busulfan and Metronidazole: An Often Forgotten but Significant Drug Interaction by Gulbis, Alison M, Culotta, Kirk S, Jones, Roy B, Andersson, Borje S

“…Objective: To report the case of a clinically significant drug interaction between intravenous busulfan and oral metronidazole observed through busulfan…”
Get full text

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities by Popat, Uday R., Pasvolsky, Oren, Bassett Jr, Roland, Mehta, Rohtesh S., Olson, Amanda, Chen, Julianne, Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Gulbis, Alison M., Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Oran, Betul, Saini, Neeraj, Shigle, Terri Lynn, Srour, Samer A., Ramdial, Jeremy L., Rezvani, Katayoun, Qazilbash, Muzaffar H., Andersson, Borje S., Champlin, Richard E., Shpall, Elizabeth J.

“…•Myeloablative fractionated busulfan regimen results in low nonrelapse mortality without a higher relapse rate.•This regimen is a viable myeloablative…”
Get full text